Clinical trial
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
NCT00070538 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00070538 |
|---|---|
| Title | VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies |
| Official title | A Phase I Study Of VNP40101M And Cytarabine For Patients With Hematologic Malignancies |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | cytarabine, laromustine |
| Start date | Jun 1, 2003 |
| Primary completion | Sep 1, 2004 |
| Completion | Jan 1, 2008 |
| First posted | Oct 7, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: